News & Events
- March 17, 2025
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
- September 25, 2024
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
- August 20, 2024
Entera Bio to Participate in Upcoming Investor and Scientific Conferences – HCW, ASBMR, and Evercore
- August 20, 2024
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
- March 14, 2024
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
- November 14, 2023
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
- September 12, 2023
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
- June 7, 2023
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
- May 3, 2023
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
- April 26, 2023
Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board
- April 3, 2023
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
- March 31, 2023
